Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Datamonitors' Scimedent Health, Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Scimedent Health, Corp. since January 2007.
– Provides intelligence on Scimedent Health, Corp.'s M&A, strategic partnerships and alliances, capital raising and private equity transactions. – Detailed reports of various financial transactions undertaken by Scimedent Health, Corp. and its subsidiaries since 2007. – Information about key financial and legal advisors for Scimedent Health, Corp.'s financial deals transactions. – Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
This report includes Scimedent Health, Corp.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Scimedent Health, Corp.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Reasons to Purchase:
– Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances. – Form an independent opinion about Scimedent Health, Corp.’s growth strategies through the organic and inorganic activities undertaken since 2007. – Track your competitors’ business structure and growth strategies.
Our reports have been used by over 10K customers, including:
175 pages •
By The Business Research Company
• Jun 2021
Major players in the fertility drugs market are Merck & Co., Ferring Pharmaceuticals, Bayer, Berlex Laboratories Inc., Janssen Pharmaceutical Inc., Pfizer, Novartis AG, Procter & Gamble Pharmaceutical, Zydus Pharma and LIVZON. The global drugs for infertility market is expected to grow from $3.48 billion in 2020 to $3.94 billion in...
The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination,...
236 pages •
By Global Industry Analysts
• Apr 2021
- Global Biopharmaceutical Fermentation Systems Market to Reach $14.8 Billion by 2027
- Amid the COVID-19 crisis, the global market for Biopharmaceutical Fermentation Systems estimated at US$10.9 Billion in the year 2020, is projected to reach a revised size of US$14.8 Billion by 2027, growing at aCAGR of...
124 pages •
By Global Industry Analysts
• Apr 2021
- Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market to Reach $5.7 Billion by 2027
- Amid the COVID-19 crisis, the global market for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$5.7 Billion by 2027,...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
The global cell dissociation market size is projected to reach USD 561 million by 2026 from USD 282 million in 2021, at a CAGR of 14.7% during the forecast period. The growth in this market is attributed to the prevalence of cell based research, the increasing number of pharmaceutical and biotechnology companies. Moreover, the growth opportunities...
“Neutropenia - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and...
Global Hospital Care Partnering 2014 to 2021 provides the full collection of Hospital Care disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Hospital Care partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hospital...
The biosimilar market reached a value of US$ 7.7 Billion in 2020. This market is currently being driven by a number of factors such as patent expires of blockbuster biological drugs, lower prices, rising prevalence of chronic diseases, and cost-saving initiatives from governments and third-party payers. Catalyzed by these factors, the market...
The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Biosimilars partnering deals Disclosed headlines, upfronts, milestones and royalties...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.